Actively Recruiting
Real-World Study of Chemotherapy With Durvalumab Followed by Maintenance Durvalumab or Durvalumab Plus Olaparib for Advanced or Recurrent Endometrial Cancer
Led by AstraZeneca · Updated on 2026-09-30
150
Participants Needed
49
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multi-center, prospective, non-interventional study in Germany to collect real-world clinical and patient-reported data from women with primary advanced FIGO stage III or IV or recurrent endometrial cancer receiving first-line treatment. The study evaluates two maintenance therapies following chemotherapy with Carboplatin, Paclitaxel, and Durvalumab CPD, focusing on outcomes in patients with different tumor DNA mismatch repair statuses. The goal is to understand the effectiveness, safety, and patient experiences with these treatments in routine clinical practice. Participants receive first-line CPD chemotherapy. Those with DNA mismatch repair deficient tumors dMMR cohort receive maintenance therapy with durvalumab alone if their disease is controlled after chemotherapy. Participants with DNA mismatch repair proficient tumors pMMR cohort receive maintenance therapy with durvalumab and olaparib under similar conditions. Treatment decisions are based on standard care guidelines and made jointly by patients and their physicians. The study follows patients over time to observe treatment duration and transitions. During the study, participants complete patient-reported outcome questionnaires to assess quality of life and symptom changes after chemotherapy. Clinical data including time to next treatment and progression-free survival are collected up to 46 months. The study also tracks maintenance therapy duration, chemotherapy duration, and timing between chemotherapy and maintenance start. Safety and treatment use are monitored as part of routine care. Overall, the study provides long-term real-world insights into first-line and maintenance therapy for endometrial cancer.
CONDITIONS
Brief Title
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here